Skip to main content
. 2018 Apr 20;9(30):21166–21181. doi: 10.18632/oncotarget.24989

Figure 4. Metformin potentiates Venetoclax and BAY-1143572 in cell-type dependent manner.

Figure 4

10,000 cells (A, E, I, Daudi, B, F, J. SUDHL-4, C, G, K. KPUM-UH1, D, H, L. Jeko-1) were plated per well of a 96-well plate and treated with dose response series of both metformin (results for concentrations 0, 100 μM,10 mM shown) and Doxorubicin (0–10 μM; Figure 4A–4D), or Venetoclax (0–10 μM; Figure 4E–4H) or BAY-1143572 (0–100 μM; Figure 4I–4L) or Idelalisib (0–100 μM; Figure 4M–4P) in triplicate. Viability after 3 days was analyzed using MTS assay. Briefly 20 μL of MTS reagent was added to cells and incubated for 2 hours and absorbance at 490 nm was read using a Biotek plate reader. Relative absorbance is calculated after setting the average absorbance of no treatment control as 1. Error bars represent standard deviation between triplicates.